Update on Regulatory Status of Hypertension, Biomarkers and Arrhythmia Monitoring in Clinical Trials. Join us at FDA White Oak Campus to examine proarrhythmia, hypertension and biomarkers.

In Session 1, leading industry professionals will speak on panels discussing:

  • Regulations for ECG/QT
  • The double-negative conundrum
  • Alternative methods for assay sensitivity assessment in routine Phase 1 QT Studies
  • Covid-19 and prolonged QT

In Session 2, the following topics will be discussed:

  • Small increases in blood pressure and CV risk
  • Intermittent versus chronic use of hypertension drugs

In Session 3, the meeting faculty will dive into:

  • Biomarkers

In Session 4, the panelists will discuss hot topics in the field such as:

  • Biologics/cardiomyopathy and vaccine development
  • MACE
  • Gene therapies
  • Wearables

We will be joined by professionals from FDA Regulatory, Cardiac Safety Consultants, Ltd., Eli Lilly, Richmond Pharmacology, University of Connecticut, Stanford University, University of Pennsylvania, Cleveland Clinic, Clario, Mass General, DSI, Penn Medicine, and UCSF.

Our CEO Jorg Taubel will be presenting on the topic of alternative methods for assay sensitivity assessment in routine Phase 1 QT Studies, as well as taking part in a panel about Proarrhythmia.

Latest news

Richmond Appoints Lisa Campbell as Director of Regulatory Strategy

April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read more

Von Willebrand Disease Trial – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol

April 2, 2025
Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...
Read more

Events

Swiss Biotech Day 2025

5–6 May 2025
Richmond Pharmacology is pleased to confirm our participation at Swiss Biotech Day 2025
View event